Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma.

Abstract

A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.

Metadata

Item Type:	Article
Authors/Creators:	Ansari, J. Hussain, S.A. https://orcid.org/0000-0003-1552-511X Ansari, A. Glaholm, J.
Copyright, Publisher and Additional Information:	© 2013 Ansari et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. https://creativecommons.org/licenses/by-nc/3.0/
Keywords:	metastatic RCC; vascular endothelial growth factor receptor inhibitor; molecular targeted agent; clear-cell carcinoma
Dates:	Published: 28 February 2013 Accepted: 22 November 2013
Institution:	The University of Sheffield
Academic Units:	The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Oncology (Sheffield)
Depositing User:	Symplectic Sheffield
Date Deposited:	02 May 2019 11:10
Last Modified:	02 May 2019 11:13
Status:	Published
Publisher:	Dove Medical Press
Refereed:	Yes
Identification Number:	10.2147/BTT.S25862
Related URLs:	PubMed URL
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:145610

CORE (COnnecting REpositories)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma.

Abstract

Metadata

Download

Published Version

Export

Statistics